{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:06:48Z","timestamp":1790287608769,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.yebeh.2024.110159","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T13:17:23Z","timestamp":1732195043000},"page":"110159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and tolerability of celastrol and edaravone in the multiple-hit rat model of infantile spasms"],"prefix":"10.1016","volume":"162","author":[{"given":"Oleksii","family":"Shandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D.","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhu B.","family":"Mowrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon L.","family":"Mosh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristea S.","family":"Galanopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yebeh.2024.110159_b0005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110159_b0010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00004691-200311000-00004","article-title":"Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms\/West syndrome)","volume":"20","author":"Hrachovy","year":"2003","journal-title":"J Clin Neurophysiol"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0387-7604(01)00268-6","article-title":"What is West syndrome?","volume":"23","author":"Dulac","year":"2001","journal-title":"Brain Develop"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110159_b0020","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1212\/01.WNL.0000127773.72699.C8","article-title":"Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society","volume":"62","author":"Mackay","year":"2004","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110159_b0025","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","article-title":"Infantile spasms: a U.S. consensus report","volume":"51","author":"Pellock","year":"2010","journal-title":"Epilepsia"},{"issue":"24","key":"10.1016\/j.yebeh.2024.110159_b0030","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1212\/WNL.0b013e318259e2cf","volume":"78","author":"Go","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2024.110159_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1167.2011.03029.x","article-title":"Immune-mediated epilepsies","volume":"52","author":"Granata","year":"2011","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110159_b0040","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1528-1167.2010.02586.x","article-title":"Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants","volume":"51","author":"Hong","year":"2010","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2024.110159_b0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2012.11.009","article-title":"Ketogenic diet for infantile spasms refractory to first-line treatments: an open prospective study","volume":"105","author":"Pires","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110159_b0050","doi-asserted-by":"crossref","unstructured":"Knupp KG, Coryell J, Nickels KC, Ryan N, Leister E, Loddenkemper T, Grinspan Z, Hartman AL, Kossoff EH, Gaillard WD, Mytinger JR, Joshi S, Shellhaas RA, Sullivan J, Dlugos D, Hamikawa L, Berg AT, Millichap J, Nordli DR, Jr., Wirrell E, and Pediatric Epilepsy Research C. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol 2015.","DOI":"10.1002\/ana.24594"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110159_b0055","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0022-3476(83)80606-4","article-title":"Double-blind study of ACTH vs prednisone therapy in infantile spasms","volume":"103","author":"Hrachovy","year":"1983","journal-title":"J Pediatr"},{"issue":"5 Pt 1","key":"10.1016\/j.yebeh.2024.110159_b0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0022-3476(05)81379-4","article-title":"High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms","volume":"124","author":"Hrachovy","year":"1994","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study","volume":"97","author":"Baram","year":"1996","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.yebeh.2024.110159_b0070","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","article-title":"Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study","volume":"38","author":"Vigevano","year":"1997","journal-title":"Epilepsia"},{"issue":"9447","key":"10.1016\/j.yebeh.2024.110159_b0075","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(04)17400-X","article-title":"The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial","volume":"364","author":"Lux","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110159_b0080","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1528-1167.2010.02716.x","article-title":"Comment on \u201cInfantile spasms: a U.S. consensus report\u201d","volume":"51","author":"Galanopoulou","year":"2010","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2024.110159_b0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2024.110159_b0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.nbd.2015.04.015","article-title":"Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies","volume":"79","author":"Galanopoulou","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ana.21082","article-title":"Model of infantile spasms induced by N-methyl-D-aspartic acid in prenatally impaired brain","volume":"61","author":"Velisek","year":"2007","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0100","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1111\/j.1528-1167.2011.03357.x","article-title":"Prenatal stress promotes development of spasms in infant rats","volume":"53","author":"Yum","year":"2012","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110159_b0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1203\/PDR.0b013e31819d9076","article-title":"Infantile spasms and Down syndrome: a new animal model","volume":"65","author":"Cortez","year":"2009","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1528-1167.2007.01377.x","article-title":"A new animal model of infantile spasms with unprovoked persistent seizures","volume":"49","author":"Lee","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110159_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107786","article-title":"Acthar(R) Gel (repository corticotropin injection) dose-response relationships in an animal model of epileptic spasms","volume":"116","author":"Le","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110159_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2015.04.019","article-title":"Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms","volume":"82","author":"Frost","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"27","key":"10.1016\/j.yebeh.2024.110159_b0125","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1523\/JNEUROSCI.0915-09.2009","article-title":"A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment","volume":"29","author":"Price","year":"2009","journal-title":"J Neurosci"},{"issue":"Pt 6","key":"10.1016\/j.yebeh.2024.110159_b0130","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/brain\/awp107","article-title":"Targeted loss of Arx results in a developmental epilepsy mouse model and recapitulates the human phenotype in heterozygous females","volume":"132","author":"Marsh","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2024.110159_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105329","article-title":"Early 17beta-estradiol treatment reduces seizures but not abnormal behaviour in mice with expanded polyalanine tracts in the Aristaless related homeobox gene (ARX)","volume":"153","author":"Loring","year":"2021","journal-title":"Neurobiol Dis"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110159_b0140","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1523\/JNEUROSCI.0572-22.2022","article-title":"Cortical parvalbumin-positive interneuron development and function are altered in the APC conditional knockout mouse model of infantile and epileptic spasms syndrome","volume":"43","author":"Ryner","year":"2023","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2024.110159_b0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.nbd.2016.11.002","article-title":"APC conditional knock-out mouse is a model of infantile spasms with elevated neuronal beta-catenin levels, neonatal spasms, and chronic seizures","volume":"98","author":"Pirone","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0150","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.nbd.2009.11.011","article-title":"A model of symptomatic infantile spasms syndrome","volume":"37","author":"Scantlebury","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110159_b0155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/epi.12424","article-title":"CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms","volume":"55","author":"Briggs","year":"2014","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110159_b0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eplepsyres.2013.10.015","article-title":"Efficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms","volume":"108","author":"Jequier Gygax","year":"2014","journal-title":"Epilepsy Res"},{"issue":"9","key":"10.1016\/j.yebeh.2024.110159_b0165","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/j.1528-1167.2011.03173.x","article-title":"Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms","volume":"52","author":"Ono","year":"2011","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0170","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.nbd.2011.03.021","article-title":"A pulse rapamycin therapy for infantile spasms and associated cognitive decline","volume":"43","author":"Raffo","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110159_b0175","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/epi.16975","article-title":"Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions","volume":"62","author":"Akman","year":"2021","journal-title":"Epilepsia"},{"issue":"Suppl Suppl 2","key":"10.1016\/j.yebeh.2024.110159_b0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/epi4.12280","article-title":"Acquired parvalbumin-selective interneuronopathy in the multiple-hit model of infantile spasms: a putative basis for the partial responsiveness to vigabatrin analogs?","volume":"3","author":"Katsarou","year":"2018","journal-title":"Epilepsia Open"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0185","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s11064-017-2282-0","article-title":"Preclinical screening for treatments for infantile spasms in the multiple hit rat model of infantile spasms: an update","volume":"42","author":"Galanopoulou","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1016\/j.yebeh.2024.110159_b0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.apcsb.2017.01.005","article-title":"Inflammation in epileptic encephalopathies","volume":"108","author":"Shandra","year":"2017","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2024.110159_b0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/epi.13785","article-title":"Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy","volume":"58","author":"Barker-Haliski","year":"2017","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110159_b0200","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bcp.2006.08.014","article-title":"Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid","volume":"72","author":"Lee","year":"2006","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0205","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2006-10-050807","article-title":"Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation","volume":"109","author":"Sethi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0210","doi-asserted-by":"crossref","first-page":"e58391","DOI":"10.1371\/journal.pone.0058391","article-title":"Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2\/ERG fusion gene expressing prostate cancer","volume":"8","author":"Shao","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110159_b0215","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ajh.2010.75","article-title":"Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1","volume":"23","author":"Yu","year":"2010","journal-title":"Am J Hypertens"},{"issue":"9","key":"10.1016\/j.yebeh.2024.110159_b0220","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jash.2017.07.004","article-title":"Celastrol synergizes with oral nifedipine to attenuate hypertension in preeclampsia: a randomized, placebo-controlled, and double blinded trial","volume":"11","author":"Xiao","year":"2017","journal-title":"J Am Soc Hypertens"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110159_b0225","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14737175.2023.2251687","article-title":"Oral edaravone - introducing a flexible treatment option for amyotrophic lateral sclerosis","volume":"23","author":"Pattee","year":"2023","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0230","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mus.27768","article-title":"Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment","volume":"67","author":"Genge","year":"2023","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40268-022-00391-6","article-title":"Analysis of the US safety data for edaravone (Radicava((R))) from the third year after launch","volume":"22","author":"Genge","year":"2022","journal-title":"Drugs R D"},{"issue":"12","key":"10.1016\/j.yebeh.2024.110159_b0240","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.clinthera.2023.09.025","article-title":"Pharmacokinetics of edaravone oral suspension in patients with amyotrophic lateral sclerosis","volume":"45","author":"Shimizu","year":"2023","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110159_b0245","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cpdd.925","article-title":"Evaluation of pharmacokinetics, safety, and drug-drug interactions of an oral suspension of edaravone in healthy adults","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110159_b0250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3164\/jcbn.17-62","article-title":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?","volume":"62","author":"Watanabe","year":"2018","journal-title":"J Clin Biochem Nutr"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110159_b0255","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cell.2017.10.011","article-title":"Edaravone: a new drug approved for ALS","volume":"171","author":"Rothstein","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0260","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Writing","year":"2017","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110159_b0265","doi-asserted-by":"crossref","first-page":"e0258614","DOI":"10.1371\/journal.pone.0258614","article-title":"Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]","volume":"17","author":"Brooks","year":"2022","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.yebeh.2024.110159_b0270","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis","volume":"267","author":"Lunetta","year":"2020","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0275","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1097\/MJT.0000000000001742","article-title":"Edaravone oral suspension: a neuroprotective agent to treat amyotrophic lateral sclerosis","volume":"31","author":"Singh","year":"2024","journal-title":"Am J Ther"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0280","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/STROKEAHA.118.024351","article-title":"Effect of edaravone on neurological symptoms in real-world patients with acute ischemic stroke","volume":"50","author":"Kobayashi","year":"2019","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0285","first-page":"109","article-title":"Safety and efficacy of edaravone combined with alteplase for patients with acute ischemic stroke: a systematic review and meta-analysis","volume":"76","author":"Hu","year":"2021","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0290","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/svn-2018-000221","article-title":"Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0295","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0972-2327.82794","article-title":"A randomized controlled clinical trial to compare the safety and efficacy of edaravone in acute ischemic stroke","volume":"14","author":"Sharma","year":"2011","journal-title":"Ann Indian Acad Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110159_b0300","doi-asserted-by":"crossref","first-page":"13637","DOI":"10.3390\/ijms150813637","article-title":"Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2","volume":"15","author":"Yang","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110159_b0305","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/CAD.0b013e3283514b68","article-title":"Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol","volume":"23","author":"Huang","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0310","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.110.165654","article-title":"Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway","volume":"334","author":"Zhu","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110159_b0315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2008.06.012","article-title":"Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus","volume":"18","author":"Kamida","year":"2009","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110159_b0320","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/jps.24482","article-title":"Intravenous administration of stable-labeled N-acetylcysteine demonstrates an indirect mechanism for boosting glutathione and improving redox status","volume":"104","author":"Zhou","year":"2015","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0325","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10543409808835241","article-title":"An extension of Satterthwaite's approximation applied to pharmacokinetics","volume":"8","author":"Nedelman","year":"1998","journal-title":"J Biopharm Stat"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0330","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1528-1167.2011.03127.x","article-title":"The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study","volume":"52","author":"O'Callaghan","year":"2011","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110159_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1651-2227.1984.tb09889.x","article-title":"Infantile spasms: modern practical aspects","volume":"73","author":"Riikonen","year":"1984","journal-title":"Acta Paediatr Scand"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0340","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1528-1157.1983.tb04874.x","article-title":"A prospective study of infantile spasms: clinical and therapeutic correlations","volume":"24","author":"Lombroso","year":"1983","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2024.110159_b0345","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00431-012-1813-6","article-title":"Diagnosis delay in West syndrome: misdiagnosis and consequences","volume":"171","author":"Auvin","year":"2012","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0350","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.0013-9580.2004.30503.x","article-title":"Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone","volume":"45","author":"Kivity","year":"2004","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110159_b0355","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1331.2008.02498.x","article-title":"Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin","volume":"16","author":"Cohen-Sadan","year":"2009","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1379\/CSC-269.1","article-title":"Induction of heat shock proteins in differentiated human and rodent neurons by celastrol","volume":"12","author":"Chow","year":"2007","journal-title":"Cell Stress Chaperones"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110159_b0365","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1471-4159.2005.03253.x","article-title":"Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity","volume":"94","author":"Cleren","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.yebeh.2024.110159_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-6-1","article-title":"Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation","volume":"6","author":"Wang","year":"2005","journal-title":"BMC Neurosci"},{"issue":"12","key":"10.1016\/j.yebeh.2024.110159_b0375","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00109-007-0251-9","article-title":"Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response","volume":"85","author":"Zhang","year":"2007","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110159_b0380","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000090364","article-title":"Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis","volume":"2","author":"Kiaei","year":"2005","journal-title":"Neurodegener Dis"},{"issue":"13","key":"10.1016\/j.yebeh.2024.110159_b0385","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1016\/j.bmcl.2010.05.066","article-title":"Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells","volume":"20","author":"Sun","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110159_b0390","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12640-012-9374-z","article-title":"The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions","volume":"24","author":"Jantas","year":"2013","journal-title":"Neurotox Res"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0395","doi-asserted-by":"crossref","first-page":"400","DOI":"10.21037\/atm-21-7015","article-title":"Regulating mitochondrial homeostasis and inhibiting inflammatory responses through Celastrol","volume":"10","author":"Tao","year":"2022","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110159_b0400","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.3390\/molecules20058242","article-title":"Celastrol Protects against antimycin A-induced insulin resistance in human skeletal muscle cells","volume":"20","author":"Abu Bakar","year":"2015","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0405","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0006-291X(90)90759-G","article-title":"The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria","volume":"172","author":"Sassa","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.yebeh.2024.110159_b0410","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-024-03246-9","article-title":"Celastrol ameliorates hypoxic-ischemic brain injury in neonatal rats by reducing oxidative stress and inflammation","author":"Hu","year":"2024","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0415","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1083\/jcb.200408091","article-title":"A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death","volume":"167","author":"Nasrallah","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.yebeh.2024.110159_b0420","first-page":"7420507","article-title":"Celastrol protects against cerebral ischemia\/reperfusion injury in mice by inhibiting glycolysis through targeting HIF-1alpha\/PDK1 axis","volume":"2022","author":"Chen","year":"2022","journal-title":"Oxid Med Cell Longev"},{"issue":"12","key":"10.1016\/j.yebeh.2024.110159_b0425","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123171","article-title":"A missense variant in PDK1 associated with severe neurodevelopmental delay and epilepsy","volume":"10","author":"Vaz","year":"2022","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.yebeh.2024.110159_b0430","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ejhg.2011.121","article-title":"Copy number variants and infantile spasms: evidence for abnormalities in ventral forebrain development and pathways of synaptic function","volume":"19","author":"Paciorkowski","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110159_b0435","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/epi4.12102","article-title":"Metabolic etiologies in West syndrome","volume":"3","author":"Salar","year":"2018","journal-title":"Epilepsia Open"},{"issue":"21","key":"10.1016\/j.yebeh.2024.110159_b0440","doi-asserted-by":"crossref","first-page":"E2955","DOI":"10.1073\/pnas.1516321113","article-title":"PDK1-Akt pathway regulates radial neuronal migration and microtubules in the developing mouse neocortex","volume":"113","author":"Itoh","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"10.1016\/j.yebeh.2024.110159_b0445","doi-asserted-by":"crossref","first-page":"13064","DOI":"10.1073\/pnas.0808400106","article-title":"Selective induction of neocortical GABAergic neurons by the PDK1-Akt pathway through activation of Mash1","volume":"106","author":"Oishi","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.yebeh.2024.110159_b0450","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fnins.2015.00181","article-title":"Genotype-phenotype correlation in neuronal migration disorders and cortical dysplasias","volume":"9","author":"Kato","year":"2015","journal-title":"Front Neurosci"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110159_b0455","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/08830738050200042001","article-title":"X-linked lissencephaly with abnormal genitalia as a tangential migration disorder causing intractable epilepsy: proposal for a new term, \u201cinterneuronopathy\u201d","volume":"20","author":"Kato","year":"2005","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0460","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.042515","article-title":"Arx expansion mutation perturbs cortical development by augmenting apoptosis without activating innate immunity in a mouse model of X-linked infantile spasms syndrome","volume":"13","author":"Siehr","year":"2020","journal-title":"Dis Model Mech"},{"issue":"220","key":"10.1016\/j.yebeh.2024.110159_b0465","doi-asserted-by":"crossref","first-page":"p. 220ra12","DOI":"10.1126\/scitranslmed.3007231","article-title":"Neonatal estradiol stimulation prevents epilepsy in Arx model of X-linked infantile spasms syndrome","volume":"6","author":"Olivetti","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0470","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/epi4.12062","article-title":"Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders","volume":"2","author":"Katsarou","year":"2017","journal-title":"Epilepsia Open"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110159_b0475","first-page":"1624","article-title":"Effects of an antistroke agent MCl-186 on cerebral arachidonate cascade","volume":"271","author":"Watanabe","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110159_b0480","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/01.STR.0000182241.07096.06","article-title":"Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain","volume":"36","author":"Zhang","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.yebeh.2024.110159_b0485","doi-asserted-by":"crossref","first-page":"6908884","DOI":"10.1155\/2022\/6908884","article-title":"Edaravone attenuated particulate matter-induced lung inflammation by inhibiting ROS-NF-kappaB signaling pathway","volume":"2022","author":"Zeng","year":"2022","journal-title":"Oxid Med Cell Longev"},{"issue":"13","key":"10.1016\/j.yebeh.2024.110159_b0490","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1093\/emboj\/cdg332","article-title":"Evidence that reactive oxygen species do not mediate NF-kappaB activation","volume":"22","author":"Hayakawa","year":"2003","journal-title":"EMBO J"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110159_b0495","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1096\/fasebj.10.7.8635688","article-title":"Antioxidant and redox regulation of gene transcription","volume":"10","author":"Sen","year":"1996","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110159_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/ph14010029","article-title":"Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis","volume":"14","author":"Cho","year":"2020","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:07:09Z","timestamp":1733717229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024005419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":100,"alternative-id":["S1525505024005419"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110159","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of celastrol and edaravone in the multiple-hit rat model of infantile spasms","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110159"}}